Supriya Lifescience announced the outcome of its Board Meeting held on February 09, 2026. The Board approved the Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. Furthermore, the Board sanctioned the re-appointment of Dr. Neelam Yashpal Arora and the appointment of Mr. Manish Panchal and Mr. Kothandaraman Hari as Additional Independent Directors. Committee structures were also ratified.
Outcome of Board Meeting on February 09, 2026
The Board of Directors of Supriya Lifescience Ltd. convened on Monday, February 09, 2026, and approved several key items, primarily concerning financial results and board composition changes.
Financial Results Approved
The Board approved the Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. These results were accompanied by the Limited Review Report from the Statutory Auditors.
Standalone Quarterly Performance Highlights (Q3 FY26 vs. Q3 FY25)
The unaudited results show key figures for the quarter ended December 31, 2025, compared to the previous year’s corresponding quarter (In million):
- Total Income: 2,090.51 (vs. 1,877.45 in Q3 FY24).
- Profit/(Loss) for the period from Continuing Operations: 496.75 (vs. 467.83 in Q3 FY24).
- Basic Earnings Per Share (Continuing): ₹6.17 (vs. ₹5.82 in Q3 FY24).
Nine-Month Performance Highlights (FY26 vs. FY25)
For the nine months ended December 31, 2025:
- Total Income: 5,593.57 (vs. 5,192.16 in FY25).
- Profit/(Loss) for the period from Continuing Operations: 1,348.92 (vs. 1,375.76 in FY25).
- Basic Earnings Per Share (Continuing): ₹16.76 (vs. ₹17.07 in FY25).
The financial statements noted that an exceptional item of (₹4.58) million was recognized during the period, related to the impact identified from the New Labour Codes effective November 21, 2025.
Changes in Directorate Approved
The Board approved significant changes to its structure, subject to shareholder approval:
- Dr. Neelam Yashpal Arora (DIN: 01603068): Re-appointed as Non-Executive Independent Woman Director for a second term of five consecutive years, effective from March 25, 2026, to March 24, 2031. Dr. Arora holds extensive experience in education, commerce, and law, with over 31 years in teaching.
- Mr. Manish Panchal (DIN: 08431492): Appointed as Additional Independent Director, effective from February 09, 2026, to February 08, 2031. Mr. Panchal is a Business Leader with over 32 years of cross-industry experience in sectors including Chemicals, Pharmaceuticals, and Medical Devices, and is active in Investment Banking.
- Mr. Kothandaraman Hari (DIN: 08901674): Appointed as Additional Independent Director, effective from February 09, 2026, to February 08, 2031. Mr. Hari is a capital markets professional with over 28 years of experience, having been an Executive Vice President at the National Stock Exchange of India (NSE).
All three appointees confirmed they are not debarred from holding office.
Reconstitution of Board Committees
The Board also reconstituted the composition of its standing committees:
Audit Committee
- Chairman: Mr. Hari K.
- Members: Dr. Ganapati Dadasaheb Yadav, Dr. Satish Waman Wagh, and Mr. Manish Panchal.
Nomination and Remuneration Committee
- Chairman: Mr. Hari K.
- Members: Dr. Sunil Subhash Bhagwat and Mr. Manish Panchal.
Stakeholders’ Relationship Committee
- Chairman: Mr. Manish Panchal.
- Members: Dr. Saloni Satish Wagh and Dr. Satish Waman Wagh.
The Board Meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.
Source: BSE
